Your search returned 2 results.

Results
	1.	β-Galactosidase treatment is a common first-stage modification of the three major subtypes of Gc protein to GcMAF. [electronic resource] by Uto, Yoshihiro Yamamoto, Syota Mukai, Hirotaka Ishiyama, Noriko Takeuchi, Ryota Nakagawa, Yoshinori Hirota, Keiji Terada, Hiroshi Onizuka, Shinya Hori, Hitoshi Producer: 20120807 In: Anticancer research vol. 32 Availability: No items available. Save to lists Add to cart (remove)
	2.	Degalactosylated/desialylated human serum containing GcMAF induces macrophage phagocytic activity and in vivo antitumor activity. [electronic resource] by Kuchiike, Daisuke Uto, Yoshihiro Mukai, Hirotaka Ishiyama, Noriko Abe, Chiaki Tanaka, Daichi Kawai, Tomohito Kubo, Kentaro Mette, Martin Inui, Toshio Endo, Yoshio Hori, Hitoshi Producer: 20130904 In: Anticancer research vol. 33 Availability: No items available. Save to lists Add to cart (remove)

Refine your search